Judith Aberg
#45,368
Most Influential Person Now
Researcher
Judith Aberg's AcademicInfluence.com Rankings
Judith Abergphilosophy Degrees
Philosophy
#7194
World Rank
#10368
Historical Rank
Logic
#7069
World Rank
#8695
Historical Rank
Download Badge
Philosophy
Judith Aberg's Degrees
- Doctorate Medicine Columbia University
- Masters Public Health Columbia University
Why Is Judith Aberg Influential?
(Suggest an Edit or Addition)According to Wikipedia, Judith Aberg is an American physician who is the George Baehr Professor of Clinical Medicine at Mount Sinai Hospital. She was appointed Dean of System Operations for Clinical Sciences at the Icahn School of Medicine at Mount Sinai. Her research considered infectious diseases, including HIV/AIDS and COVID-19.
Judith Aberg's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. (2008) (2385)
- An inflammatory cytokine signature predicts COVID-19 severity and survival (2020) (1522)
- Robust neutralizing antibodies to SARS-CoV-2 infection persist for months (2020) (939)
- Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. (2012) (742)
- Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. (2003) (660)
- National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2. (2015) (626)
- Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine Association of the Infectious Diseases Society of America. (2004) (518)
- Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. (2014) (435)
- Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV Medicine Association of the Infectious Diseases Society of America. (2014) (389)
- Introductions and early spread of SARS-CoV-2 in the New York City area (2020) (366)
- Convalescent plasma treatment of severe COVID-19: a propensity score–matched control study (2020) (364)
- Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047 (2002) (347)
- Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer (2020) (291)
- Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study (2014) (286)
- Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV medicine association of the Infectious Diseases Society of America. (2014) (254)
- Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: Recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group. (2000) (210)
- Phase I Evaluation of the Safety and Pharmacokinetics of Murine-Derived Anticryptococcal Antibody 18B7 in Subjects with Treated Cryptococcal Meningitis (2005) (199)
- Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. (2002) (192)
- Primary care guidelines for the management of persons infected with human immunodeficiency virus: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. (2004) (190)
- Pulmonary cryptococcosis in patients without HIV infection. (1999) (174)
- Effect of Efavirenz on the Pharmacokinetics of Simvastatin, Atorvastatin, and Pravastatin: Results of AIDS Clinical Trials Group 5108 Study (2005) (172)
- Undetectable plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected persons. (2005) (167)
- Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed. (2002) (164)
- Recombinant Interferon-γlb as Adjunctive Therapy for AIDS-Related Acute Cryptococcal Meningitis (2004) (163)
- Short-Term Effects of Cannabinoids in Patients with HIV-1 Infection (2003) (153)
- Aspirin Attenuates Platelet Activation and Immune Activation in HIV-1-Infected Subjects on Antiretroviral Therapy: A Pilot Study (2013) (137)
- Phase I Dose Escalation Trial Evaluating the Pharmacokinetics, Anti-Human Cytomegalovirus (HCMV) Activity, and Safety of 1263W94 in Human Immunodeficiency Virus-Infected Men with Asymptomatic HCMV Shedding (2002) (137)
- Sex differences in nevirapine rash. (2001) (135)
- Safety of discontinuation of maintenance therapy for disseminated histoplasmosis after immunologic response to antiretroviral therapy. (2004) (133)
- A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087. (2005) (131)
- SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months (2020) (130)
- Humoral response and PCR positivity in patients with COVID-19 in the New York City region, USA: an observational study (2020) (128)
- Aging, inflammation, and HIV infection. (2012) (127)
- Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1-infected women. (2014) (126)
- Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy: an international observational study. (2004) (118)
- Convalescent plasma treatment of severe COVID-19: A matched control study (2020) (117)
- Discontinuation of Mycobacterium avium Complex Prophylaxis in Patients with Antiretroviral TherapyInduced Increases in CD4+ Cell Count (2000) (111)
- Cardiovascular Complications in HIV Management: Past, Present, and Future (2009) (106)
- The Science and Value of Diversity: Closing the Gaps in Our Understanding of Inclusion and Diversity. (2019) (106)
- A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206 (2010) (106)
- Fish Oil and Fenofibrate for the Treatment of Hypertriglyceridemia in HIV-Infected Subjects on Antiretroviral Therapy: Results of ACTG A5186 (2008) (104)
- Coronavirus 2019 and People Living With Human Immunodeficiency Virus: Outcomes for Hospitalized Patients in New York City (2020) (102)
- Covid-19 and People with HIV Infection: Outcomes for Hospitalized Patients in New York City. (2020) (99)
- Recombinant interferon- gamma 1b as adjunctive therapy for AIDS-related acute cryptococcal meningitis. (2004) (97)
- Clinical Characteristics of Hospitalized Covid-19 Patients in New York City (2020) (93)
- Humoral immune response and prolonged PCR positivity in a cohort of 1343 SARS-CoV 2 patients in the New York City region (2020) (91)
- Acute Kidney Injury in Hospitalized Patients with COVID-19 (2020) (91)
- Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers (2005) (91)
- Eradication of AIDS-related disseminated mycobacterium avium complex infection after 12 months of antimycobacterial therapy combined with highly active antiretroviral therapy. (1998) (90)
- An inflammatory cytokine signature helps predict COVID-19 severity and death (2020) (86)
- Self-Perception of HIV Risk and Candidacy for Pre-Exposure Prophylaxis Among Men Who Have Sex with Men Testing for HIV at Commercial Sex Venues in New York City. (2014) (82)
- Machine Learning to Predict Mortality and Critical Events in a Cohort of Patients With COVID-19 in New York City: Model Development and Validation (2020) (81)
- Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks. (2012) (80)
- Neuropsychiatric Complications of Antiretroviral Therapy (2006) (79)
- Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE). (2019) (79)
- Awareness of post-exposure HIV prophylaxis in high-risk men who have sex with men in New York City (2011) (77)
- Implementation of HIV testing at 2 New York City bathhouses: from pilot to clinical service. (2009) (75)
- Health needs of HIV-infected women in the United States: insights from the women living positive survey. (2011) (75)
- Three patients with X-linked agammaglobulinemia hospitalized for COVID-19 improved with convalescent plasma (2020) (74)
- Three patients with X-linked agammaglobulinemia hospitalized for COVID-19 improved with convalescent plasma (2020) (74)
- Development of national and multiagency HIV care quality measures. (2010) (71)
- Primary Care Guidance for Persons With Human Immunodeficiency Virus: 2020 Update by the HIV Medicine Association of the Infectious Diseases Society of America. (2020) (69)
- Clinical impact of patient population differences and genomic variation in efavirenz therapy (2008) (66)
- Effects of pitavastatin and pravastatin on markers of immune activation and arterial inflammation in HIV (2017) (63)
- Pitavastatin versus pravastatin in adults with HIV-1 infection and dyslipidaemia (INTREPID): 12 week and 52 week results of a phase 4, multicentre, randomised, double-blind, superiority trial. (2017) (63)
- Safety and Efficacy of Extended-Release Niacin for the Treatment of Dyslipidaemia in Patients with HIV Infection: Aids Clinical Trials Group Study A5148 (2006) (62)
- Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection. (2020) (62)
- Clinical Utility of Monitoring Serum Cryptococcal Antigen (sCRAG) Titers in Patients with AIDS-Related Cryptococcal Disease (2000) (60)
- Protease inhibitor-based antiretroviral therapy and glucose tolerance in pregnancy: AIDS Clinical Trials Group A5084. (2007) (60)
- Use of Physiological Data From a Wearable Device to Identify SARS-CoV-2 Infection and Symptoms and Predict COVID-19 Diagnosis: Observational Study (2021) (58)
- Effect of Ritonavir/Saquinavir on Stereoselective Pharmacokinetics of Methadone: Results of AIDS Clinical Trials Group (ACTG) 401 (2001) (58)
- Machine Learning to Predict Mortality and Critical Events in COVID-19 Positive New York City Patients: A Cohort Study. (2020) (58)
- Localized osteomyelitis due to Mycobacterium avium complex in patients with Human Immunodeficiency Virus receiving highly active antiretroviral therapy. (2002) (56)
- A Randomized Placebo Controlled Trial of Aspirin Effects on Immune Activation in Chronically Human Immunodeficiency Virus-Infected Adults on Virologically Suppressive Antiretroviral Therapy (2017) (56)
- A pilot study of the discontinuation of antifungal therapy for disseminated cryptococcal disease in patients with acquired immunodeficiency syndrome, following immunologic response to antiretroviral therapy. (2002) (55)
- Comparison of once-daily versus twice-daily combination antiretroviral therapy in treatment-naive patients: results of AIDS clinical trials group (ACTG) A5073, a 48-week randomized controlled trial. (2010) (50)
- Discontinuation of Mycobacterium avium complex prophylaxis in patients with antiretroviral therapy-induced increases in CD4+ cell count. A randomized, double-blind, placebo-controlled trial. AIDS Clinical Trials Group 362 Study Team. (2000) (50)
- Convalescent Plasma for the Treatment of COVID-19: Perspectives of the National Institutes of Health COVID-19 Treatment Guidelines Panel (2020) (49)
- Anti-α4β7 therapy targets lymphoid aggregates in the gastrointestinal tract of HIV-1–infected individuals (2018) (49)
- Low level viremia and virologic failure in persons with HIV infection treated with antiretroviral therapy. (2019) (47)
- Maraviroc Can Improve Lipid Profiles in Dyslipidemic Patients with HIV: Results from the MERIT Trial (2011) (46)
- Differentiation of IL-17–Producing Effector and Regulatory Human T Cells from Lineage-Committed Naive Precursors (2014) (46)
- Clinical outcomes and immunologic characteristics of Covid-19 in people with HIV. (2020) (46)
- A study of discontinuing maintenance therapy in human immunodeficiency virus-infected subjects with disseminated Mycobacterium avium complex: AIDS Clinical Trial Group 393 Study Team. (2003) (46)
- Aging with HIV in the ART era. (2017) (46)
- Glycated Hemoglobin A(1c) as screening for diabetes mellitus in HIV-infected individuals. (2012) (44)
- Convalescent Plasma for the Treatment of Severe COVID‐19 Infection in Cancer Patients (2020) (42)
- Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG Study A5108 (2006) (42)
- COVID-19: Staging of a New Disease (2020) (41)
- High Rates of Anal High-Grade Squamous Intraepithelial Lesions in HIV-Infected Women Who Do Not Meet Screening Guidelines (2017) (40)
- Lipid management in patients who have HIV and are receiving HIV therapy. (2009) (40)
- Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study. (2020) (39)
- The virologic and immunologic effects of cyclosporine as an adjunct to antiretroviral therapy in patients treated during acute and early HIV-1 infection. (2010) (38)
- Management of lipid disorders in patients living with HIV (2015) (38)
- The impact of sex and contraceptive therapy on the plasma and intracellular pharmacokinetics of zidovudine (2006) (37)
- Treatment with pravastatin and fenofibrate improves atherogenic lipid profiles but not inflammatory markers in ACTG 5087. (2010) (36)
- Machine Learning to Predict Mortality and Critical Events in COVID-19 Positive New York City Patients (2020) (34)
- Lack of Pharmacokinetic Interactions Between Pitavastatin and Efavirenz or Darunavir/Ritonavir (2014) (33)
- mRNA-1273 but not BNT162b2 induces antibodies against polyethylene glycol (PEG) contained in mRNA-based vaccine formulations (2022) (33)
- Rationale and design of the Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE): Effects of pitavastatin on coronary artery disease and inflammatory biomarkers. (2019) (33)
- Invasive Fungal Sinusitis and Meningitis Due toArthrographis kalrae in a Patient with AIDS (2001) (32)
- Immunoglobulin G immunosuppression of multiple sclerosis. Suppression of all three major lymphocyte subsets. (1993) (29)
- Effects of atorvastatin on biomarkers of immune activation, inflammation, and lipids in virologically suppressed, human immunodeficiency virus-1-infected individuals with low-density lipoprotein cholesterol <130 mg/dL (AIDS Clinical Trials Group Study A5275). (2017) (28)
- Care for transgender persons. (2013) (28)
- Immune response to hepatitis B vaccine in HIV-infected subjects using granulocyte-macrophage colony-stimulating factor (GM-CSF) as a vaccine adjuvant: ACTG study 5220. (2010) (28)
- Hyperparathyroidism and complications associated with vitamin D deficiency in HIV-infected adults in New York City, New York. (2012) (27)
- Clinical Outcomes and Immunologic Characteristics of Coronavirus Disease 2019 in People With Human Immunodeficiency Virus (2020) (27)
- Management of dyslipidemia in HIV-infected patients. (2011) (27)
- Natural History of Intestinal Microsporidiosis among Patients Infected with Human Immunodeficiency Virus (1999) (27)
- Treatment with convalescent plasma in solid organ transplant recipients with COVID‐19: Experience at large transplant center in New York City (2020) (27)
- Infectious diseases handbook (2001) (27)
- Uridine supplementation in the treatment of HIV lipoatrophy: results of ACTG 5229 (2010) (26)
- Dyslipidemia in HIV patients. (2005) (26)
- Association of Vaccination with the Persistence of Post-COVID Symptoms (2022) (26)
- Global Pharmacovigilance for Antiretroviral Drugs: Overcoming Contrasting Priorities (2011) (25)
- The Changing Face of HIV Care: Common Things Really Are Common (2006) (25)
- Effect of simultaneous versus staggered dosing on pharmacokinetic interactions of protease inhibitors (2003) (24)
- Safety and Tolerability of Sequential Pegylated IFN-α2a and Tenofovir for Hepatitis B Infection in HIV+ Individuals (2007) (24)
- HIV policy: the path forward--a joint position paper of the HIV Medicine Association of the Infectious Diseases Society of America and the American College of Physicians. (2009) (23)
- Retrospective cohort study of clinical characteristics of 2199 hospitalised patients with COVID-19 in New York City (2020) (23)
- Coronary heart disease in people infected with HIV (2010) (22)
- High Accuracy of Common HIV-Related Oral Disease Diagnoses by Non-Oral Health Specialists in the AIDS Clinical Trial Group (2015) (22)
- Effect of ritonavir/saquinavir on stereoselective pharmacokinetics of methadone: results of AIDS Clinical Trials Group (ACTG) 401. (2001) (21)
- Prediabetes and diabetes among HIV‐infected adults in Cameroon (2016) (21)
- Prevalence and Significance of G6PD Deficiency in Patients of an Urban HIV Clinic (2008) (19)
- Nonnucleoside Reverse Transcriptase Inhibitor Resistance Among Antiretroviral-Naive HIV-Positive Pregnant Women (2003) (19)
- Lower peripheral blood CD14+ monocyte frequency and higher CD34+ progenitor cell frequency are associated with HBV vaccine induced response in HIV infected individuals. (2011) (19)
- Targeting thrombogenicity and inflammation in chronic HIV infection (2019) (19)
- Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: results of the AIDS Clinical Trials Group A5211. (2009) (18)
- Gonorrhea and Chlamydia Case Detection Increased When Testing Increased in a Multisite US HIV Cohort, 2004–2014 (2017) (17)
- HIV: primary and secondary prophylaxis for opportunistic infections. (2010) (17)
- Diversity in the US Infectious Diseases Workforce: Challenges for Women and Underrepresented Minorities. (2017) (16)
- A Randomized Controlled Trial of Palifermin (Recombinant Human Keratinocyte Growth Factor) for the Treatment of Inadequate CD4+ T-Lymphocyte Recovery in Patients with HIV-1 Infection on Antiretroviral Therapy (2014) (16)
- Oral shedding of herpesviruses in HIV-infected patients with varying degrees of immune status (2017) (16)
- Atherosclerotic Cardiovascular Disease and Anti-Retroviral Therapy (2016) (15)
- Cardiac risk: not so simple. (2010) (15)
- Fish Oil and Fenofibrate for the Treatment of Hypertriglyceridemia in HIV-Infected Subjects on Antiretroviral Therapy: (2009) (15)
- Steady-State Pharmacokinetics, Cord Blood Concentrations, and Safety of Ritonavir-Boosted Fosamprenavir in Pregnancy (2013) (14)
- Transfusion reactions associated with COVID‐19 convalescent plasma therapy for SARS‐CoV‐2 (2020) (14)
- Convalescent plasma in patients hospitalised with COVID-19 (2021) (14)
- Comparison of Direct and Indirect Measurement of LDL-C in HIV-Infected Individuals: ACTG 5087 (2007) (14)
- Assessing statin effects on cardiovascular pathways in HIV using a novel proteomics approach: Analysis of data from INTREPID, a randomized controlled trial (2018) (14)
- Anogenital human papillomavirus virus DNA and sustained response to the quadrivalent HPV vaccine in women living with HIV-1 (2018) (14)
- Pulmonary cryptococcosis in normal hosts: treat or observe? (2003) (14)
- Prothymosin α variants isolated from CD8+ T cells and cervicovaginal fluid suppress HIV-1 replication through type I interferon induction. (2015) (14)
- Assessment of Coronary Artery Disease With Computed Tomography Angiography and Inflammatory and Immune Activation Biomarkers Among Adults With HIV Eligible for Primary Cardiovascular Prevention (2021) (13)
- A Randomized Placebo-Controlled Trial of Sarilumab in Hospitalized Patients with Covid-19 (2021) (13)
- The Rapid Prediction of Carbapenem Resistance in Patients With Klebsiella pneumoniae Bacteremia Using Electronic Medical Record Data (2018) (13)
- Virologic and Serologic Outcomes of Mono Versus Dual HBV Therapy and Characterization of HIV/HBV Coinfection in a US Cohort (2014) (13)
- Tolerance of Efavirenz-Induced Central Nervous System Side Effects in HIV-Infected Individuals with a History of Substance Abuse (2003) (13)
- Uptake and virological outcomes of single‐ versus multi‐tablet antiretroviral regimens among treatment‐naïve youth in the HIV Research Network (2019) (12)
- HCV Screening and Treatment Uptake Among Patients in HIV Care During 2014–2015 (2019) (12)
- Combined estimation of disease progression and retention on antiretroviral therapy among treated individuals with HIV in the USA: a modelling study. (2019) (12)
- Design Aspects of a Case-Control Clinical Investigation of the Effect of HIV on Oral and Gastrointestinal Soluble Innate Factors and Microbes (2014) (11)
- Management of dyslipidemia and other cardiovascular risk factors in HIV-infected patients: case-based review. (2006) (11)
- Associations of Plasma Cytokine and Microbial Translocation Biomarkers With Immune Reconstitution Inflammatory Syndrome (2017) (11)
- Concerns regarding a randomized study of the timing of antiretroviral therapy in zimbabweans with AIDS and acute cryptococcal meningitis. (2010) (11)
- Cardiovascular risk among HIV-positive patients on antiretroviral therapy. (2003) (11)
- Prostaglandin production in chronic progressive multiple sclerosis (1990) (10)
- Presence of Macrolide Resistance in Respiratory Flora of HIV-Infected Patients Receiving Either Clarithromycin or Azithromycin for Mycobacterium avium Complex Prophylaxis (2001) (10)
- Assessment of Obesity and Cardiometabolic Status by Integrase Inhibitor Use in REPRIEVE: A Propensity-Weighted Analysis of a Multinational Primary Cardiovascular Prevention Cohort of People With Human Immunodeficiency Virus (2021) (10)
- Pafuramidine for Pneumocystis jiroveci pneumonia in HIV-infected individuals (2007) (10)
- Risk factors for tuberculin skin test conversion among HIV-infected patients in New York City. (2012) (10)
- HIV and cardiovascular risk factors. (2001) (10)
- Virologic Outcome of Using Tenofovir/Emtricitabine to Treat Hepatitis B in HIV-Coinfected Patients (2011) (10)
- GM-CSF Fails to Improve Immune Responses to Booster Hepatitis B Vaccination in HIV-Infected Individuals (2011) (8)
- Effects of felodipine on plasma digoxin levels and haemodynamics in patients with heart failure (1989) (8)
- Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE Trial. (2020) (8)
- Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1 (2021) (8)
- Prothymosin-α Variants Elicit Anti-HIV-1 Response via TLR4 Dependent and Independent Pathways (2016) (8)
- Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE Trial. (2020) (8)
- HIV viral suppression after transition from having no healthcare coverage and relying on Ryan White HIV/AIDS Program Support to Medicaid or private health insurance. (2019) (8)
- Drug-drug interactions with newer antiretroviral agents. (2008) (8)
- Discontinuation of Antiretroviral Therapy Postpartum: No Evidence for Altered Viral Set Point (2007) (8)
- Cardiovascular Risk and Health Among People With Human Immunodeficiency Virus (HIV) Eligible for Primary Prevention: Insights From the REPRIEVE Trial (2021) (8)
- Randomized Trial Comparing Dose Reduction and Growth Factor Supplementation for Management of Hematological Side Effects in HIV/Hepatitis C Virus Patients Receiving Pegylated-Interferon and Ribavirin (2011) (7)
- Cardiovascular and endothelial disease in HIV infection (2005) (7)
- Aging and HIV infection: focus on cardiovascular disease risk. (2020) (7)
- Differential Plasma Protein Regulation and Statin Effects in Human Immunodeficiency Virus (HIV)-Infected and Non-HIV-Infected Patients Utilizing a Proteomics Approach (2020) (6)
- Pitavastatin 4 mg Provides Superior LDL-C Reduction vs. Pravastatin 40 mg Over 12 weeks in HIV-Infected Adults with Dyslipidemia, the INTREPID Trial (2013) (6)
- Reconstitution of immunity against opportunistic infections in the era of potent antiretroviral therapy. (2000) (6)
- Cure of acute hepatitis C in HIV co-infection? (2004) (6)
- A tale of two fungi in a person with HIV. (2006) (6)
- After 52 Weeks, Pitavastatin Superior to Pravastatin on LDL-C Lowering in Patients with HIV† (2014) (6)
- Clinical research in the lay press: irresponsible journalism raises a huge dose of doubt. (2006) (6)
- Decreasing risk among HIV patients on opioid therapy for chronic pain: Development of the TOWER intervention for HIV care providers (2019) (6)
- Asymptomatic SARS-CoV-2 Infection Is Common Among ART-Treated People With HIV (2022) (5)
- High-sensitivity C-reactive protein levels do not decrease with the use of statins in all persons with HIV infection. (2011) (5)
- Cryptococcal disease: implications of recent clinical trials on treatment and management. (1997) (5)
- Chronic High Risk Prescription Opioid Use Among Persons With HIV (2021) (5)
- Efficacy and Safety of Sarilumab in Hospitalized Patients With Coronavirus Disease 2019: A Randomized Clinical Trial (2022) (4)
- Women and HIV : An Overview (2005) (4)
- Soluble Levels of Receptor for Advanced Glycation Endproducts (RAGE) and Progression of Atherosclerosis in Individuals Infected with Human Immunodeficiency Virus: ACTG NWCS 332 (2016) (4)
- Pitavastatin 4 mg vs. Pravastatin 40 mg in HIV Dyslipidemia: Post-Hoc Analysis of the INTREPID Trial Based on the Independent CHD Risk Factor of Age† (2014) (4)
- Letter in Response to the New SHEA Guideline for Healthcare Workers with Hepatitis B Virus, Hepatitis C Virus, and/or Human Immunodeficiency Virus (2010) (4)
- Guidelines for the Management of Persons Infected With HIV : 2013 Update by the HIV Medicine Association of the Infectious Diseases Society of America (2013) (4)
- Haemodynamic and renal effects of felodipine in young and elderly subjects (1998) (4)
- 2.P.10 Effects of erythromycin on plasma fluvastatin levels: A pharmacokinetic study (1997) (4)
- Differential Plasma Protein Regulation and Statin Effects in HIV-infected and Non-HIV-infected Patients Utilizing a Proteomics Approach Protein Regulation and Statin Effects in HIV. (2020) (4)
- Proteomic Signature of Subclinical Coronary Artery Disease in People with HIV: Analysis of the REPRIEVE Mechanistic Substudy. (2022) (3)
- 561. Safety of Remdesivir vs Standard Care in Patients with Moderate Covid-19 (2020) (3)
- Comparing longitudinal CD4 responses to cART among non-perinatally HIV-infected youth versus adults: Results from the HIVRN Cohort (2017) (3)
- 548. Baseline characteristics associated with clinical improvement and mortality in hospitalized patients with moderate COVID-19 (2020) (3)
- COVID-19 Vaccination Rates in a Global HIV Cohort. (2021) (3)
- Factors Associated with Systemic Immune Activation Indices in a Global Primary Cardiovascular Disease Prevention Cohort of People with HIV on Antiretroviral Therapy. (2022) (3)
- Factors Associated With Gaps in Medicaid Enrollment Among People With HIV and the Effect of Gaps on Viral Suppression (2018) (2)
- Successful recruitment of a multi-site international randomized placebo-controlled trial in people with HIV with attention to diversity of race and ethnicity: critical role of central coordination (2020) (2)
- A mobile health intervention in HIV primary care: supporting patients at risk for ART non-adherence (2020) (2)
- 557. Impact of Concomitant Hydroxychloroquine Use on Safety and Efficacy of Remdesivir in Moderate COVID-19 Patients (2020) (2)
- A case of nocardia osteomyelits--is HIV to blame? (2002) (2)
- Assessing Antiretroviral Use During Gaps in HIV Primary Care Using Multisite Medicaid Claims and Clinical Data (2017) (2)
- HIV Counseling and Testing for Household Members of HIV-Infected Individuals in Africa: Should Prevention Programs Focus on Home-Based Rather than Clinic-Based Outreach? (2011) (2)
- Diet in a global cohort of adults with HIV at low-to-moderate traditional cardiovascular disease risk (2022) (1)
- JCL roundtable: Managing lipid disorders in patients with HIV. (2017) (1)
- Recommendations of the International AIDS Antiretroviral Treatment of Adult HIV Infection : 2008 (2008) (1)
- Treatment of Human Immunodeficiency Virus in Adults—Reply (2012) (1)
- Clinical Utility of Monitoring Serum Cryptococcal Antigen (sCRAG) Titers in Patients with AIDS-Related Cryptococcal Disease (2000) (1)
- Challenges of Statins in HIV Hyperlipidemia (2013) (1)
- Soluble levels of receptor for advanced glycation endproducts and dysfunctional high-density lipoprotein in persons infected with human immunodeficiency virus (2018) (1)
- Risk Factors Associated with Sexually Transmitted Infections among Pre-Exposure Prophylaxis Users in an Urban Multi-Clinic Healthcare System (2017) (1)
- Optimizing Cardiovascular Risk Prevention in an Urban HIV Clinic (2016) (1)
- 86 – Gender-Specific Issues in the Metabolic Complications of HIV Disease and Its Treatment (2004) (1)
- Anti-α4β7 therapy targets lymphoid aggregates in the gastrointestinal tract of HIV-1 infected individuals (2018) (1)
- Immunologic characteristics of acute COVID-19 in people with HIV (2020) (1)
- Ideal cardiovascular health, biomarkers, and coronary artery disease in persons with HIV (2022) (1)
- Low bone mineral density: HIV related? (2007) (1)
- Genetic Predictors of Cervical Dysplasia in African American HIV-Infected Women: ACTG DACS 268 (2013) (1)
- The importance of methods for site performance evaluation in REPRIEVE, a longitudinal, global, multicenter trial (2022) (1)
- An Evaluation of Baseline Kidney Function in the REPRIEVE Trial of Pitavastatin in Human Immunodeficiency Virus. (2020) (1)
- HIV Primary Care (2007) (1)
- Geographical Differences in the Self-Reported Functional Impairment of People with HIV and Associations with Cardiometabolic Risk. (2022) (1)
- Idiopathic hypoparathyroidism in a blind, deaf, elderly woman with dementia. (1996) (1)
- Acknowledgment to Reviewers (2019) (1)
- Use of Physiological Data From a Wearable Device to Identify SARS-CoV-2 Infection and Symptoms and Predict COVID-19 Diagnosis: Observational Study (Preprint) (2020) (1)
- Oral Cytokine Levels Are More Linked to Levels of Plasma and Oral HIV-1 RNA Than to CD4+ T-Cell Counts in People With HIV (2020) (1)
- Informative Censoring—A Cause of Bias in Estimating COVID-19 Mortality Using Hospital Data (2023) (1)
- Effects of Sex, Existing Antibodies, and HIV-1–Related and Other Baseline Factors on Antibody Responses to Quadrivalent HPV Vaccine in Persons With HIV (2021) (0)
- What Is the Prognosis for Using the Pneumonia Severity Index To Make Site-of-Care Decisions In Community-Acquired Pneumonia ? (2003) (0)
- Pro-inflammatory and pro-resolving lipid mediators of inflammation in HIV: effect of aspirin intervention (2023) (0)
- Evaluating the effect of atorvastatin exposure and vitamin D levels on lipid outcomes in people with HIV-1 with suppressed HIV-1 RNA and LDL cholesterol <130 mg/dL. (2022) (0)
- Abstract 368: Increased Platelet Activity in HIV-Infected Subjects on Antiretroviral Therapy Is Inhibited with Low-Dose Aspirin (2012) (0)
- 166 The Impact of Concurrent HIV-1 Infection on the Management of Patients With Inflammatory Bowel Disease (2016) (0)
- Higher Dose Oral Fluconazole for the Treatment of AIDS-related Cryptococcal Meningitis (HIFLAC)—report of A5225, a multicentre, phase I/II, two-stage, dose-finding, safety, tolerability and efficacy randomised, amphotericin B-controlled trial of the AIDS Clinical Trials Group (2023) (0)
- Cardiovascular/Metabolic Toxicities (2005) (0)
- Clinical Infectious Disease: Prophylaxis of Opportunistic Infections in HIV Infection (2008) (0)
- Thanks to Reviewers2005 (2005) (0)
- 510. Elevated IL-1β level as a predictor of inflammation and death in COVID-19 (2020) (0)
- Safety, Tolerability, and Pharmacokinetics of Anti-SARS-CoV-2 Immunoglobulin Intravenous (Human) Investigational Product (COVID-HIGIV) in Healthy Adults: a Randomized, Controlled, Double-Blinded, Phase 1 Study (2023) (0)
- Impact of screen and staging on survival of hepatocellular carcinoma (HCC) in HCV/HIV co-infected patients (2013) (0)
- Complications of Acquired Immunodeficiency Syndrome (2009) (0)
- Discontinuity in Medicaid Coverage Among Young Adults with HIV. (2019) (0)
- New goals for viral suppression in HIV treatment in even the most experienced of patients (2009) (0)
- Cytomegalovirus IgG Titer and Coronary Artery Disease in People with HIV. (2022) (0)
- Improving Cardiovascular Risk Prevention in HIV Primary Care (2017) (0)
- Hepatitis A and B Immunization in Persons Infected with HIV (2011) (0)
- Therapeutic trials for long COVID-19: A call to action from the interventions taskforce of the RECOVER initiative (2023) (0)
- Soluble Levels of Receptor for Advanced Glycation Endproducts (RAGE) and Progression of Atherosclerosis in Individuals Infected with Human Immunodeficiency Virus: ACTG NWCS 332 (2016) (0)
- Thanks to Reviewers2003 (2003) (0)
- The 2009 HIV Primary Care Guidelines (2009) (0)
- Thanks to Reviewers2002 (2002) (0)
- LB13. Candida auris in NYC: A Health System’s Experience Treating the Emerging Drug-Resistant Yeast (2018) (0)
- Thanks to Reviewers2001 (2001) (0)
- CASE REPORTS Invasive Fungal Sinusitis and Meningitis Due to Arthrographis kalrae in a Patient with AIDS (2001) (0)
- PROPHYLAXIS OF OPPORTUNISTIC INFECTIONS IN THE ERA OF POTENT ANTIRETROVIRAL THERAPY : AN UPDATE (1999) (0)
- Cases From the Field FDG-PET Imaging in the Diagnosis of HIV-Associated Multicentric Castleman Disease : Something Is Still Missing 116 (2012) (0)
- Sex Differences in Subclinical Atherosclerosis and Systemic Immune Activation/Inflammation Among People With Human Immunodeficiency Virus in the United States (2022) (0)
- Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind placebo-controlled trial (2022) (0)
- Effect of host factors and COVID-19 infection on the humoral immune repertoire in treated HIV (2023) (0)
- Best of AIDS 2003: Clinical Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047, by Fichtenbaum et al (2003) (0)
- 935. Effect of Tesamorelin in People with HIV with and without Dorsocervical Fat: Post Hoc Analysis of Phase III Double Blind Placebo Control Trial (2020) (0)
- Thanks to Reviewers2004 (2004) (0)
- Coronary Artery Plaque Composition and Severity Relate to the Inflammasome in People With Treated Human Immunodeficiency Virus (2023) (0)
- Reply to Monroe and Brown. (2014) (0)
- Identification of pre-infection markers and differential plasma protein expression following SARS-CoV-2 infection in people living with HIV (2023) (0)
- 860. Immediate Access to Post-Exposure Prophylaxis (PEP) Through a 24/7 New York City PEP Hotline (2018) (0)
- Pitavastatin 4 mg Superior to Pravastatin 40 mg on LDL-C Reduction in HIV-Positive Patients with Dyslipidemia with and without Ritonavir-based Therapy† (2015) (0)
- An inflammatory cytokine signature predicts COVID-19 severity and survival (2020) (0)
- Human Immunodeficiency Virus Medicine Association Pain Management Guidelines Needed to Curb Opioid Epidemic. (2018) (0)
- 635 HIV VIRAL LOAD INDEPENDENTLY PREDICTS SURVIVAL IN HIVINFECTED PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) (2013) (0)
- O35 PREDICTING SURVIVAL OF HIV-INFECTED PATIENTS WITH LIVER CANCER – THE SHILCA SCORE AND STAGING MODEL (2014) (0)
- Toward Safer Opioid Prescribing in HIV care (TOWER): a mixed-methods, cluster-randomized trial (2022) (0)
- Rationale and Design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) RCT# NCT02344290 (2019) (0)
- Antiretroviral Treatment (ART) of Adult HIV Infection (2010) (0)
- CORONARY ARTERY DISEASE IN LOW- TO INTERMEDIATE-RISK ASYMPTOMATIC PEOPLE WITH HIV: COMPARISON TO ASYMPTOMATIC COMMUNITY AND STABLE CHEST PAIN POPULATIONS WITHOUT KNOWN HIV (2023) (0)
- JAMA Peer Reviewers in 2004 (2016) (0)
- Thanks to Reviewers2015 (2015) (0)
- Lineage-Committed Naive Precursors and Regulatory Human T Cells from Producing Effector - Differentiation of IL-17 (2014) (0)
- HIV and Dyslipidemia (2020) (0)
- What's New in HIV Guidelines (2009) (0)
- Clash of the microbes: let's bring back the good guys. (2013) (0)
- Machine Learning to Predict Mortality and Critical Events in a Cohort of Patients With COVID-19 in New York City: Model Development and Validation (Preprint) (2020) (0)
- “Big data” and Gram-negative Resistance: A Multiple Logistic Regression Model Using EMR Data to Predict Carbapenem Resistance in Patients with Klebsiella pneumoniae Bloodstream Infection (2017) (0)
- Reply to Allan-Blitz and Klausner. (2017) (0)
- Prevention of Hepatitis Infection in HIV-Infected Patients (2012) (0)
- Confronting Rising Drug Prices in HIV (2016) (0)
- Book review (2000) (0)
- Changes in Body Mass Index with Longer-term Integrase Inhibitor Use: a Longitudinal Analysis of REPRIEVE data. (2023) (0)
- Case files from the Bellevue Hospital Center at New York University--lipoatrophy following long-term antiretroviral therapy. (2005) (0)
- What's New in HIV Primary Care and Preventive Medicine (2014) (0)
- Corrigendum to: Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE Trial. (2020) (0)
- Thanks to Reviewers2000 (2000) (0)
This paper list is powered by the following services:
Other Resources About Judith Aberg
What Schools Are Affiliated With Judith Aberg?
Judith Aberg is affiliated with the following schools:
